SURGE Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- SURGE Therapeutics's estimated annual revenue is currently $697.5k per year.
- SURGE Therapeutics's estimated revenue per employee is $77,500
Employee Data
- SURGE Therapeutics has 9 Employees.
- SURGE Therapeutics grew their employee count by 29% last year.
SURGE Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Head Formulations | Reveal Email/Phone |
5 | Head Formulations | Reveal Email/Phone |
6 | VP, Clinical Operations | Reveal Email/Phone |
7 | CXO | Reveal Email/Phone |
SURGE Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is SURGE Therapeutics?
SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.
keywords:N/AN/A
Total Funding
9
Number of Employees
$697.5k
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | -10% | N/A |
#4 | $0.7M | 9 | -71% | $138.8M |
#5 | $0.7M | 9 | -25% | N/A |